• 1
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:28932917.
  • 2
    Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:13481355.
  • 3
    Wright TL. Introduction to chronic hepatitis B infection. Am J Gastroenterol 2006;101(Suppl 1):S1S6.
    Direct Link:
  • 4
    Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:4146.
  • 5
    Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, El-Serag HB, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013;108:13141321.
  • 6
    Kao WY, Su CW, Chau GY, Lui WY, Wu CW, Wu JC. A comparison of prognosis between patients with hepatitis B and C virus-related hepatocellular carcinoma undergoing resection surgery. World J Surg 2011;35:858867.
  • 7
    Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 2012;1:4855.
  • 8
    Bei R, Mizejewski GJ. Alpha fetoprotein is more than a hepatocellular cancer biomarker: from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine. Curr Mol Med 2011;11:564581.
  • 9
    Liu C, Xiao GQ, Yan LN, Li B, Jiang L, Wen TF, et al. Value of alpha-fetoprotein in association with clinicopathological features of hepatocellular carcinoma. World J Gastroenterol 2013;19:18111819.
  • 10
    Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 2003;9:59025908.
  • 11
    Vollmer CM Jr, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, et al. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res 1999;59:30643067.
  • 12
    Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, et al. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 1999;59:31343142.
  • 13
    Grimm CF, Ortmann D, Mohr L, Michalak S, Krohne TU, Meckel S, et al. Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice. Gastroenterology 2000;119:11041112.
  • 14
    Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, et al. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res 2001;61:87828786.
  • 15
    Cany J, Barteau B, Tran L, Gauttier V, Archambeaud I, Couty JP, et al. AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J Hepatol 2011;54:115121.
  • 16
    Pang XH, Chen MS, Jia WH, Zhou XX. [Inhibitory effects of human AFP-derived peptide-pulsed dendritic cells on mouse hepatocellular carcinoma.] Ai Zheng 2008;27:12331238.
  • 17
    Lan YH, Li YG, Liang ZW, Chen M, Peng ML, Tang L, et al. A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma. Cancer Immunol Immunother 2007;56:10091016.
  • 18
    Wang X, Lin H, Wang Q. Specific genetic immunotherapy induced by recombinant vaccine alpha-fetoprotein-heat shock protein 70 complex. Physics Procedia 2012;33:738742.
  • 19
    Rodriguez MM, Ryu SM, Qian C, Geissler M, Grimm C, Prieto J, et al. Immunotherapy of murine hepatocellular carcinoma by alpha-fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression. Hum Gene Ther 2008;19:753759.
  • 20
    Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, et al. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol 2001;166:53005308.
  • 21
    Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 2006;12:28172825.
  • 22
    Guevara-Patino JA, Engelhorn ME, Turk MJ, Liu C, Duan F, Rizzuto G, et al. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J Clin Invest 2006;116:13821390.
  • 23
    Liu Y, Peng Y, Mi M, Guevara-Patino J, Munn DH, Fu N, et al. Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol 2009;182:59605969.
  • 24
    Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 1998;188:277286.
  • 25
    Tran L, Judor JP, Gauttier V, Geist M, Hoffman C, Rooke R, et al. The immunogenicity of the tumor-associated antigen alpha-fetoprotein is enhanced by a fusion with a transmembrane domain. J Biomed Biotechnol 2012;2012:878657.
  • 26
    He Y, Falo LD Jr. Lentivirus as a potent and mechanistically distinct vector for genetic immunization. Curr Opin Mol Ther 2007;9:439446.
  • 27
    Jin X, Moskophidis D, Mivechi NF. Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome. Cell Metab 2011;14:91103.
  • 28
    Houghton CS, Engelhorn ME, Liu C, Song D, Gregor P, Livingston PO, et al. Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. Vaccine 2007;25:53305342.
  • 29
    He Y, Zhang J, Mi Z, Robbins P, Falo LD Jr. Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol 2005;174:38083817.
  • 30
    Xiao H, Peng Y, Hong Y, Liu Y, Guo ZS, Bartlett DL, et al. Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma. J Immunol 2011;187:17881796.
  • 31
    Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005;65:99919998.
  • 32
    Price GE, Ou R, Jiang H, Huang L, Moskophidis D. Viral escape by selection of cytotoxic T cell-resistant variants in influenza A virus pneumonia. J Exp Med 2000;191:18531867.
  • 33
    Hong Y, Peng Y, Mi M, Xiao H, Munn DH, Wang GQ, et al. Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. Vaccine 2011;29:39093916.
  • 34
    Nakagawa Y, Watari E, Shimizu M, Takahashi H. One-step simple assay to determine antigen-specific cytotoxic activities by single-color flow cytometry. Biomed Res 2011;32:159166.
  • 35
    He Y, Zhang J, Donahue C, Falo LD Jr. Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006;24:643656.
  • 36
    Esslinger C, Chapatte L, Finke D, Miconnet I, Guillaume P, Levy F, et al. In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest 2003;111:16731681.
  • 37
    Arce F, Breckpot K, Collins M, Escors D. Targeting lentiviral vectors for cancer immunotherapy. Curr Cancer Ther Rev 2011;7:248260.
  • 38
    Meng WS, Butterfield LH, Ribas A, Heller JB, Dissette VB, Glaspy JA, et al. Fine specificity analysis of an HLA-A2.1-restricted immunodominant T cell epitope derived from human alpha-fetoprotein. Mol Immunol 2000;37:943950.
  • 39
    Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003;21:139176.
  • 40
    Dyall R, Bowne WB, Weber LW, LeMaoult J, Szabo P, Moroi Y, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:15531561.
  • 41
    Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, Schneck JP, et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000;13:529538.
  • 42
    van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, van Hall T, Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res 2009;69:77847792.
  • 43
    van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996;156:33083314.
  • 44
    Miles KM, Miles JJ, Madura F, Sewell AK, Cole DK. Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability. Mol Immunol;48:728732.
  • 45
    Cole DK, Edwards ES, Wynn KK, Clement M, Miles JJ, Ladell K, et al. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol 2010;185:26002610.
  • 46
    Ekeruche-Makinde J, Clement M, Cole DK, Edwards ES, Ladell K, Miles JJ, et al. T-cell receptor-optimized peptide skewing of the T-cell repertoire can enhance antigen targeting. J Biol Chem;287:3726937281.
  • 47
    Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008;105:38493854.
  • 48
    Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, et al. Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res 2012;18:64856496.
  • 49
    Letsch A, Scheibenbogen C. Quantification and characterization of specific T-cells by antigen-specific cytokine production using ELISPOT assay or intracellular cytokine staining. Methods 2003;31:143149.
  • 50
    Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152154.